Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7618865 | 0.81 | SMN1; SMN2 (0.50) | KDM4ESMN1; SMN2ALDH1A1HTT | |
| SCHEMBL539008 | 0.79 | KDM4E (0.53) | KDM4ETYRO3DYRK1BHTT | |
| SCHEMBL3861922 | 0.76 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL15718879 | 0.76 | KDM4E (0.50) | KDM4ETYRO3DYRK1B | |
| SCHEMBL3963582 | 0.76 | KDM4E (0.50) | KDM4ETYRO3DYRK1BALDH1A1 | |
| SCHEMBL369014 | 0.76 | KDM4E (0.50) | KDM4ESMN1; SMN2TYRO3DYRK1B | |
| SCHEMBL8447336 | 0.76 | ALDH1A1 (0.50) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL15571871 | 0.76 | KDM4E (0.46) | KDM4ESMN1; SMN2TYRO3DYRK1BALDH1A1 | |
| SCHEMBL31624045 | 0.74 | TYRO3 (0.46) | KDM4ESMN1; SMN2TYRO3DYRK1BALDH1A1 | |
| SCHEMBL18757838 | 0.73 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251172-A1 | PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. | 2011-10-13 | — | — | US | disclosed |
| EP-2312945-A1 | PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | Merck Sharp & Dohme Corp. (US) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010019392-A1 | PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251172-A1 | PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | BACE1, APP, PSEN1 | KDM4E 2853/4885SMN1; SMN2 962/4885TYRO3 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.